

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12805 A1

(51) International Patent Classification⁷: C12N 15/12,
A61K 38/16, 48/00

YOUNG, John [AU/AU]; 28/18 Eastbourne Road, Darling
Point, NSW 2027 (AU). DINUDOM, Anuwat [TH/AU];
17/14-18 Bennett Street, Newton, NSW 2042 (AU).

(21) International Application Number: PCT/AU00/00980

(74) Agent: FB RICE & CO; 139 Rathdowne Street, Carlton,
VIC 3053 (AU).

(22) International Filing Date: 16 August 2000 (16.08.2000)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
PQ 2239 16 August 1999 (16.08.1999) AU

(71) Applicant (*for all designated States except US*): THE
UNIVERSITY OF SYDNEY [AU/AU]; Sydney, NSW
2006 (AU).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): COOK, David,
Ian [AU/AU]; 35 Bromborough Road, Roseville, NSW
2069 (AU). FRALEY, Kristie-Ann [AU/AU]; Unit 29, 6
Murray Street, Lane Cove, NSW 2066 (AU). ISHIBASHI,
Hajime [JP/JP]; Sanbankan 1013, 6-1 Ka 3-chome,
Nagareyama, Chiba 270-0176 (JP). KOMWATANA,
Permsak [TH/AU]; 17/14-18 Bennett Street, New-
ton, NSW 2042 (AU). SANCHEZ-PEREZ, Angeles
[AU/AU]; 1 Berowra Place, Belrose, NSW 2085 (AU).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/12805 A1

(54) Title: METHODS FOR DIAGNOSIS AND TREATMENT OF HUMAN DISEASES INCLUDING HYPERTENSION

(57) Abstract: Methods for diagnosis and treatment of human disease, particularly human disease characterised by abnormal cy-
tosolic ion composition in diseased cells resulting from reduced or over activity of Na⁺ transport proteins (e.g. hypertension), are
disclosed. Additionally, the specification discloses novel Na⁺ receptors and isolated DNA molecules encoding same.

METHODS FOR DIAGNOSIS AND TREATMENT OF HUMAN DISEASES
INCLUDING HYPERTENSION

Field of the Invention:

5 The present invention relates to the diagnosis and treatment of human disease, particularly human disease characterised by abnormal cytosolic ion composition resulting from reduced or over activity of Na^+ transport proteins such as the ubiquitous Na^+ - H^+ exchanger, NHE1.

10 **Background of the Invention:**

 In recent years, over activity of Na^+ transporting systems in absorptive epithelia has been implicated in the pathogenesis of a number of major diseases including hypertension (1, 2), diabetic nephropathy (3),
cardiological syndrome X (4), ventricular hypertrophy (5), chronic pulmonary
15 hypertension (6) and cystic fibrosis (7). In the case of the hereditary hypertensive disease known as Liddle's syndrome, this activity has been attributed to a mutation of the epithelial Na^+ channel leading to loss of an inhibitory feedback mechanism which normally switches off Na^+ channel activity in response to increased intracellular Na^+ (8, 9). The mechanisms
20 that underlie this so-called homocellular regulation have been the subject of controversy, but recent experiments have revealed a previously unsuspected mechanism in which cytosolic Na^+ is "sensed" by an intracellular receptor (10). This receptor activates the G protein, G_o (11), the α -subunit of which then causes the ubiquitin-protein ligase, Nedd4 (10), to ubiquitinate and
25 inactivate the epithelial Na^+ channels (12, 13). This receptor for intracellular Na^+ is blocked by amiloride and amiloride analogs such as dimethylamiloride and benzimidazole guanidinium (10), thus explaining the previously puzzling ability of these agents to stimulate Na^+ channel activity (14).

 The present applicants have now found that the intracellular Na^+
30 receptor that controls absorptive epithelial Na^+ channels also controls the activity of the ubiquitous isoform of the Na^+ - H^+ exchanger 1, NHE1 (34). This finding suggests that intracellular Na^+ receptors form part of a general mechanism for regulating Na^+ transport proteins. It is therefore anticipated that the intracellular Na^+ receptors (and the signal-transduction systems by
35 which they control Na^+ channels, Na^+ - H^+ exchangers and other Na^+

transporting proteins) shall provide a useful target for diagnostic assays and treatments for hypertension and other diseases.

Disclosure of the Invention:

5 Thus, in a first aspect, the present invention provides a method of treatment of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na^+ transport protein, the method comprising administering to a subject having said disease an effective amount of an agent that substantially
10 restores the ion composition of the cytosol in said diseased cells to that which is found in corresponding cells from healthy tissue.

Preferably, the present invention provides a method of treatment of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na^+ transport
15 protein other than an epithelial Na^+ receptor. Most preferably, the present invention provides a method of treatment of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na^+ transport protein selected from those which are inactivated by ubiquitination (e.g. through the action of
20 a ubiquitin-protein ligase) and, particularly, from those included in the group consisting of NHE1, Na^+-H^+ exchanger 2 (NHE2) (35), Na^+-H^+ exchanger 3 (NHE3) (36), the $\text{Na}^+-\text{HCO}_3^-$ cotransporter (37) and the $\text{Na}^+\text{K}^+2\text{Cl}$ cotransporter (38).

Where the characteristic abnormal cytosolic ion composition arises
25 from reduced Na^+ transport protein activity resulting from, for example, Na^+ transport protein mutation (e.g. hereditary), depressed Na^+ transport protein expression or inappropriate activity of the Na^+ transport protein inhibitory feedback mechanism, the administered agent may be selected from gene therapy agents (e.g. recombinant adenoviruses capable of causing the
30 expression of non-mutated Na^+ transport protein) and agents capable of blocking the Na^+ transport protein inhibitory feedback mechanism. Preferred agents of the latter kind are amiloride and amiloride analogs (e.g. 6-iodoamiloride, N-dimethylamiloride, and benzimidazolylguanidium), G-protein inhibitors (e.g. GDP- β -S (39) and NF023 (40)) and agents that inhibit
35 the action of ubiquitin protein ligase on the Na^+ transport protein. Examples of this latter kind of agents are dominant negative mutants of ubiquitin (e.g.

K48R (24)), agents that prevent binding of the ubiquitin protein ligase to the Na⁺ transport protein (e.g. membrane permeable peptide analogs of the protein motif to which the ubiquitin protein ligase binds such as the WW2 and WW3 domains of Nedd4 (10)), agents that prevent ubiquitination of the Na⁺ transport protein (e.g. membrane permeable peptide analogs of the protein motif which is actually ubiquitinated, such as the N-terminal of the α - or γ -subunit of ENaC (41)) and inhibitors of the effectors of ubiquitin action on the Na⁺ transport protein including proteins involved in endocytosis (e.g. membrane permeable analogs of amphiphysin SH3 peptide(42)), and inhibitors of the degradation of the Na⁺ transport protein by proteasomes (e.g. lactacystin) or lysosomes (e.g. bafilomycin or chloroquine). Peptide analogs may be made to be membrane permeant by including a *Drosophila* antennapedia homeobox domain (15, 16).

Where the characteristic abnormal cytosolic ion composition arises from Na⁺ transport protein over activity resulting from, for example, Na⁺ transport protein mutation (e.g. hereditary), loss of the Na⁺ transport protein inhibitory feedback mechanism or inappropriate activity of other control systems (e.g. excessive levels of growth factors or glucose), the administered agent may be selected from gene therapy agents (e.g. adenoviruses capable of causing the expression of a protein participating in the Na⁺ transport protein inhibitory feedback mechanism), intracellular Na⁺ receptor activators (e.g. guanidium and guanidium analogs), G-protein activators (e.g. GTP- γ -S (43) and receptor mimetic peptides such as APP20(17)), ubiquitin ligase activators (e.g. membrane permeable peptides that mimic the effect of active G proteins on the ubiquitin protein ligase), and agents that trigger endocytosis.

An "effective amount" of the agent used in the method of the first aspect will depend upon the particular agent used, however, generally, the amount would be expected to be below about 10 mg/kg. For example, an effective amount of amiloride or an amiloride analog would typically be in the range of 1 to 3 mg/kg.

The agent may be formulated with various pharmaceutically-acceptable excipients and/or carriers commonly used in the art and prepared for administration orally (e.g. as tablets, capsules, caplets or liquids), nasally (e.g. aerosol sprays), rectally (e.g. as suppositories) and transdermally (e.g. as a transdermal patch or dermally absorbed cream or lotion). The agent may also

be formulated as an injectible solution or suspension for subcutaneous, intravenous or intramuscular administration.

In a second aspect, the present invention provides a method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na^+ transport protein, the method comprising isolating from a subject suspected of having said disease a sample of cells (such as epithelial cells or lymphocytes) and assessing said sample of cells for reduced or over activity of said Na^+ transport protein or its inhibitory feedback mechanism.

Preferably, the present invention provides a method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition resulting from reduced or over activity of a Na^+ transport protein other than an epithelial Na^+ receptor. Most preferably, the present invention provides a method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition resulting from reduced or over activity of a Na^+ transport protein selected from those which are inactivated by ubiquitination (e.g. through the action of a ubiquitin-protein ligase) and, particularly, from those included in the group consisting of NHE1, NHE2, NHE3, the $\text{Na}^+\text{-HCO}_3^-$ cotransporter and the $\text{Na}^+\text{K}^+\text{2Cl}$ cotransporters.

The sample of cells may be assessed for reduced or over activity of Na^+ transport protein by, for example, determining the rate of Na^+ -dependent intracellular pH (pH_i) recovery and comparing the value against similarly measured values from cells from healthy tissue isolated from the said suffering subject or from a control (i.e. non-diseased) subject or subjects (e.g. an average value from a panel of two or more healthy subjects).

In a variation of the invention according to the second aspect, the sample of diseased cells may be assessed for over or under expression of the Na^+ transport protein or another protein participating in the Na^+ transport protein inhibitory feedback mechanism (e.g. by polymerase chain (PCR) techniques, Northern blot hybridisation, Western blot or immunoprecipitation).

In a third aspect, the present invention provides a method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na^+ transport protein, the method comprising isolating a genomic DNA sample from a subject suspected of having said disease and assessing said sample for

the presence of a gene encoding a mutated product causative of said reduced or over activity of said Na^+ transport protein.

In a fourth aspect, the present invention provides a method of assessing a subject for a predisposition to a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na^+ transport protein, the method comprising isolating a genomic DNA sample from a subject and assessing said sample for the presence of a gene encoding a mutated product causative of reduced or over activity of said Na^+ transport protein.

In the methods of the third and fourth aspects, the human disease is preferably one which is characterised by abnormal cytosolic ion composition resulting from reduced or over activity of a Na^+ transport protein other than an epithelial Na^+ receptor. Preferably, the Na^+ transport protein is selected from the group consisting of NHE1, NHE2, NHE3, the $\text{Na}^+\text{-HCO}_3^-$ cotransporter and the $\text{Na}^+\text{K}^+\text{2Cl}$ cotransport protein). The genomic DNA sample may be isolated using routine protocols known to the art. The genomic DNA sample may be isolated from any cell sample such as whole blood, tissue biopsy or cheek cell sample. The assessment of the presence of a gene encoding a mutated product causative of reduced or over activity of the Na^+ transport protein, may be preferably achieved by hybridisation or PCR techniques using probes/primers designed to specifically hybridise to genes including mutated nucleotide sequences. The gene whose presence is to be assessed may encode a mutated Na^+ transport protein or a mutated protein participating in the Na^+ transport protein inhibitory feedback mechanism (e.g. a mutated G-protein or mutated intracellular Na^+ receptor).

The methods of the invention are applicable to, for example, hypertension, renal failure, cardiac hypertrophy and cardiological syndrome X.

The present applicants have also found that the intracellular Na^+ receptor controlling NHE1 is blocked by amiloride and amiloride analogs with the following order of potency:

6-iodoamiloride ($\text{EC}_{50} = 0.1 \mu\text{mol/l}$) < amiloride ($1.0 \mu\text{mol/l}$)
< 5-N-dimethylamiloride ($30 \mu\text{mol/l}$), benzamil ($> 30 \mu\text{mol/l}$) <
benzimidazolylguanidium ($300 \mu\text{mol/l}$)

Knowledge of these differing potencies enables the isolation of a DNA molecule encoding the intracellular Na^+ receptor controlling NHE1. That is,

by using the α -subunit of G_o as "bait" in a yeast two-hybrid technique ("The yeast two-hybrid system" edited by P.L. Bartel & S. Fields, Oxford University Press, Oxford, 1997), DNA molecules encoding interacting proteins may be isolated from suitable cDNA or genomic DNA libraries and then screened for the ability of the encoded proteins to bind 6-iodoamiloride. Further screens may be conducted for the relative inability of the encoded proteins to bind benzamil, the ability of antibodies raised to the encoded proteins to immunoprecipitate the α -subunit of G_o , and the ability of antibodies raised to the encoded proteins to block the NHE1 inhibitory feedback mechanism.

By using the yeast two-hybrid system with a constitutively active mutant of the α -subunit of G_o , it is possible to identify and isolate proteins which interact with active G_o and hence are involved in the inhibitory feedback mechanism at a loci downstream of G_o . Similarly, by using the yeast two-hybrid system with a dominant negative mutant of the α -subunit of G_o , it is possible to identify and isolate proteins such as the intracellular Na^+ receptors which are involved in the inhibitory feedback mechanism at a loci upstream of G_o .

The present applicants have isolated 5 cDNA molecules from mouse kidney and mandibular gland cDNA libraries encoding likely intracellular Na^+ receptors controlling NHE1 and Na^+ channels. The 5 candidates are nucleobindin (18), GAIP (19), rap1GAP (20) and novel proteins designated GILT (formerly designated GILT) and SCunique.

Thus, in a fifth aspect, the present invention provides an isolated DNA molecule encoding an intracellular Na^+ receptor designated GILT, said DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 1 or a nucleotide sequence showing $\geq 75\%$ (more preferably $\geq 85\%$, most preferably $\geq 95\%$) homology to that shown as SEQ ID NO: 1.

Preferably, the isolated DNA molecule of the fifth aspect encodes a protein comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 2.

In a sixth aspect, the present invention provides an isolated DNA molecule encoding an intracellular Na^+ receptor designated SCunique, said DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 3 or a nucleotide sequence showing $\geq 75\%$

(more preferably $\geq 85\%$, most preferably $\geq 95\%$) homology to that shown as SEQ ID NO: 3.

Preferably, the isolated DNA molecule of the sixth aspect encodes a protein comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 4.

The isolated DNA molecule of the fifth and sixth aspect may be incorporated into plasmids or expression vectors (including viral vectors), which may then be introduced into suitable bacterial, yeast, insect and mammalian host cells. Such host cells may be used to express the receptor encoded by the isolated DNA molecule.

Accordingly, in a seventh aspect, the present invention provides a mammalian, insect, yeast or bacterial host cell transformed with the DNA molecule of the fifth or sixth aspect.

In an eighth aspect, the present invention provides a method of producing an intracellular Na^+ receptor, comprising culturing the host cell of the seventh aspect under conditions enabling the expression of the DNA molecule and optionally recovering the expressed receptors.

Preferably, the host cell is mammalian, amphibian or of insect origin. Where the cell is mammalian, it is presently preferred that it be a Chinese hamster ovary (CHO) cell or human embryonic kidney 293 cell. Where the cell is of amphibian origin, it is presently preferred that it be a *Xenopus* oocyte. Finally, where the cell is of insect origin, it is presently preferred that it be an insect Sf9 cell.

In a ninth aspect, the present invention provides an intracellular Na^+ receptor designated GILT, said receptor comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 2, in a substantially pure form.

In a tenth aspect, the present invention provides a candidate intracellular Na^+ receptor designated SCunique, said receptor comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 4, in a substantially pure form.

In an eleventh aspect, the present invention provides an antibody which specifically binds to a receptor according to the ninth or tenth aspect. Such antibodies may be polyclonal or monoclonal and may be produced in accordance with any of the known techniques in the art.

The present applicants have also identified two variants of the nucleotide sequence encoding GILT (SEQ ID NO: 5 and SEQ ID NO: 6) and isolated and sequences some of the 5' non-coding sequence of the nucleotide sequence encoding SCunique (SEQ ID NO: 7). It is to be understood that the present invention extends to these additional nucleotide sequences.

In a twelfth aspect, the present invention provides a method for detecting agonist or antagonist agents of the receptor of the ninth or tenth aspect, comprising contacting said receptor, or a host cell transformed with and expressing the DNA molecule of the fifth or sixth aspect, with a test agent under conditions enabling the activation of said receptor, and detecting an increase or decrease in activity of the receptor.

In a further aspect, the present invention provides a nucleic acid probe/primer comprising a nucleotide sequence of 10 or more nucleotides capable of specifically hybridising to a unique sequence within a DNA molecule having a nucleotide sequence as shown as SEQ ID NO: 1 or SEQ ID NO: 3 under high stringency conditions.

As used herein, the term "high stringency conditions" refers to conditions that (i) employ low ionic strength and high temperature for washing, for example, 15 mM NaCl/1.5 mM sodium citrate/0.1% NaDodSO₄ at 50°C; (ii) employ during hybridisation a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C; or (iii) employ 50% formamide, 5 x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS and 10% dextran sulfate at 42°C in 0.2 x SSC (30 mM NaCl, 3 mM sodium citrate) and 0.1% SDS.

The term "substantially corresponding" as used herein in relation to nucleotide sequences is intended to encompass minor variations in the nucleotide sequence which due to degeneracy in the DNA code do not result in a change in the encoded protein. Further, this term is intended to encompass other minor variations in the sequence which may be required to enhance expression in a particular system but in which the variations do not result in a decrease in biological activity of the encoded protein.

The term "substantially corresponding" as used herein in relation to amino acid sequences is intended to encompass minor variations in the

amino acid sequences which do not result in a decrease in biological activity of the encoded protein. These variations may include conservative amino acid substitutions. The substitutions envisaged are:-

G, A, V, I, L, M; D, E; N, Q; S, T; K, R, H; F, Y, W, H; and
 5 P, N α -alkylamino acids.

References to percent homology values herein are calculated by the BLAST program blastn as described by Altschul, S.F. et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research Vol. 25, No. 17, pp 2289-3402 (1997).

10 The terms "comprise", "comprises" and "comprising" as used throughout the specification are intended to refer to the inclusion of a stated step, component or feature or group of steps, components or features with or without the inclusion of a further step, component or feature or group of steps, components or features.

15 The invention will hereinafter be further described by way of the following non-limiting example and accompanying figures.

Brief description of the accompanying figures:

20 Figure 1: Shows features of the Na⁺-dependent pH_i recovery measured with a zero Na⁺ pipette solution. (A) Representative experiment with 10 mM ATP in the pipette. The bar indicates the period of readmission of 155 mM Na⁺ solution to the bath. (B) Concentration-response relation for the effect of extracellular ethylisopropylamiloride (EIPA) on the Na⁺-dependent pH_i recovery. (C) The effect of modifying intracellular ATP levels.

25 Figure 2: Shows inhibition of Na⁺ -dependent pH_i recovery by cytosolic Na⁺. (A) Dependency of the Na⁺-dependent pH_i recovery on pipette Na⁺. (B) The effects of inclusion of 20 mM NMDG⁺ in the zero Na⁺ pipette solution, or by buffering intracellular and extracellular Ca²⁺ to zero by the inclusion of 20 mM 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate (BAPTA) in the pipette solution and 1 mM EGTA in the bath solution. No
 30 Ca²⁺ was added to either solution.

Figure 3: Shows that the Na⁺ feedback inhibition is mediated by a G protein. (A) The effect of the addition of 100 μ M GDP- β -S to the pipette solution. (B) The effect of the addition of 500 ng/ml activated pertussis toxin to the pipette solution. (C) The effect of the addition to the pipette solution
 35 of antibodies directed against various G protein α -subunits [AbG_{11, 12} = against

C terminals of $G\alpha_{i1}$ and $G\alpha_{i2}$; $AbG_{o,i3}$ = against C terminals of $G\alpha_o$ and $G\alpha_{i3}$; AbG_{i3} = against C terminal of $G\alpha_{i3}$; AbG_o = against N terminal of $G\alpha_o$; all 1 in 200 (vol/vol)].

Figure 4: Shows the inhibition of Na^+ feedback by intracellular amiloride. (A) Concentration-dependency of the effect of intracellular amiloride when included in 20 mM Na^+ solution. (B) The effect of the inclusion of 0.2 μ M activated recombinant α -subunit of G_o (act G_o) and amiloride (10 and 30 μ M) in the zero Na^+ pipette solution. AS and inact G_o denote controls in which activation solution or inactive $G\alpha_o$, respectively, were added to the pipette solution. (C) The effect of the inclusion of anti-Nedd4 antibody (A-Nd4; 1 μ g purified 1g/ml). GST-WW fusion protein (G-W; 0.3 mg/ml). GST-wild type-ubiquitin (wt; 0.3 mg/ml) or GST-dominant negative-ubiquitin (K48R) fusion protein (dn; 0.3 mg/ml) in the 20 mM Na^+ pipette solution. In A and C the broken lines indicate the mean rate of pH_i recovery observed with zero Na^+ pipette solution.

Figure 5: Shows the mechanisms of feedback inhibition by intracellular Na^+ of epithelial Na^+ channels in salivary duct (absorptive) cells (A) and Na^+ - H^+ exchange in salivary endpiece (secretory) cells (B). In each cell model, the apical membrane is on the left and the sodium pump (Na^+ , K^+ ATPase) is shown in the basolateral membrane on the right.

Example 1: Control of Na^+ - H^+ exchange in salivary secretory cells by an intracellular Na^+ receptor.

Materials and Methods.

Cell Preparation. Male Quackenbush strain mice were killed by cervical dislocation, and the mandibular glands were removed, finely minced, and incubated for 12 min in a physiological salt solution containing 1 mg/ml collagenase (Worthington type IV). The cell suspension was then dispersed by trituration and washed with fresh Na^+ rich bath solution containing 145 mM NaCl, 5.5 mM KCl, 1.2 mM $MgCl_2$, 7.5 mM Na-Hepes, 7.5 mM H-Hepes, 1 mM $CaCl_2$ and 10 mM glucose; the pH was adjusted to 7.4 with NaOH. The cells were filtered through a 75- μ m nylon mesh and kept on ice until required.

Patch-Clamp Techniques. A technique based on that of Demarex and coworkers (21) was used in which the whole-cell patch-clamp technique is used to control cytosolic composition while the pH-sensitive dye, BCECF, is

used to measure intracellular pH (pH_i). The patch-clamp techniques used were described (22), and the cells were loaded with BCECF by including it in the pipette solution. Except for the experiments summarised in Figure 1C, in which MgSO_4 replaced MgATP , pipettes were filled with solutions
5 containing 145 mM K-glutamate and Na-glutamate combined, 5 mM KCl, 5 mM Mes, 10 mM Mg-ATP, 1 mM EGTA, 40 mM sucrose, and 0.2 mM BCECF; the pH was adjusted to 6.0.

Measurement of pH_i . The equipment used to measure pH_i was as described (23). The chamber (0.3 ml) was continuously perfused with a Na^+ -
10 free bath solution containing 145 mM *N*-methyl-D-glucamine (NMDG)-Cl, 5.5 mM KCl, 15 mM H-Hepes, 1.2 mM MgCl_2 , 1 mM CaCl_2 , and 10 mM glucose with a pH of 7.4. Single cells in the whole-cell configuration were voltage-clamped at -30 mV. After 3 min they were illuminated alternately at 490 and 430 nm. Na^+ - H^+ exchange activity was measured by reintroducing Na^+ to the
15 bath between 2 and 3 min after the start of illumination. pH_i recovery rate was determined by fitting a linear regression to the linear phase of the pH_i recovery (i.e., between 20% and 80% of maximal recovery). Calibration of the BCECF signal was by the nigericin high- K^+ method (23).

Chemicals. Sources of chemicals and the methods for activating
20 pertussis toxin and G protein α -subunits were as reported (24, 25). Antibodies directed against the C terminals of the α -subunits of $\text{G}_{11}/\text{G}_{12}$, G_{13} and G_{13}/G_o were obtained from Calbiochem, and antibodies against the N-terminal of the α -subunit of G_o were obtained from DuPont-NEN. They were used in the pipette solution at a 1 in 200 (vol/vol) dilution of the solution
25 provided by the manufacturer. Glutathione-S-transferase (GST)-WW (G-W), GST-dominant negative-ubiquitin (K48R), and GST-wild type-ubiquitin fusion proteins were produced as described (24). The anti-Nedd4 antibody (A-Nd4) was purified IgG raised in rabbits against the C-terminal half of the protein (24, 26).

30 Results are presented as means \pm SEM. At least five cells were tested in each experimental group. Statistical significance was assessed by using Student's unpaired t test. All experiments were performed at 22°C.

Results.

35 Activity of Na^+ - H^+ exchangers was measured by a technique described by Demaurex and coworkers (21) in which the whole-cell configuration of the patch-clamp technique is used to control cytosolic composition while the pH-

sensitive dye, BCECF, measures pH_i . The cells were bathed initially in a zero Na^+ solution so that they would be unable to oppose the acid load imposed by the pipette solution using Na^+ -dependent H^+ transporters such as the Na^+ - H^+ exchanger. The bath solution then was changed to one containing 155 mM Na^+ so as to activate the Na^+ - H^+ exchanger and cause pH_i to recover toward normal levels (Fig 1A). The rate of this Na^+ -dependent pH_i recovery was used to estimate Na^+ - H^+ exchange activity. The technique was validated by demonstrating that Na^+ -dependent pH_i recovery has features consistent with its being the result of the NHE1 isoform of Na^+ - H^+ exchanger, which predominates in salivary secretory cells. It was found that the Na^+ -dependent pH_i recovery was highly sensitive to the amiloride analog, ethylisopropylamiloride (Fig. 1B), and that the recovery depended on the presence of ATP (21), being inactivated when intracellular ATP was depleted by treatment with 2-deoxy-D-glucose (5 mM) and oligomycin (5 $\mu\text{g}/\text{ml}$; Fig. 1C).

It was demonstrated that the rate of the Na^+ -dependent pH_i recovery declined with increasing pipette Na^+ concentration (Fig. 2A) in a manner similar to that described in sheep F2 Purkinje fibres (27). This inhibition evidently was caused by increased $[\text{Na}^+]_i$, because it could not be reproduced by the large organic cation, NMDG⁺ (Fig. 2B). Because intracellular free Ca^{2+} is known to regulate Na^+ - H^+ exchangers (28), an investigation was made to determine whether a change in free intracellular Ca^{2+} concentration could mediate this phenomenon. It was found that buffering cytosolic and extracellular Ca^{2+} to nominal zero did not alter the effect of increased $[\text{Na}^+]_i$ (Fig. 2B).

An investigation was also made to determine the mechanism by which $[\text{Na}^+]_i$ controls the activity of the Na^+ - H^+ exchanger. It was found that inclusion of the pipette solution of 100 μM GDP- β -S (which competitively inhibits the binding of GTP by G proteins; ref. (29) or of 500 ng/ml activated pertussis toxin (which ADP ribosylates G proteins of the G_i and G_o classes so as to prevent their interaction with receptors; ref. (30), reversed the inhibitory effect of 20 mM Na^+ (Fig. 3A and B). The ability of these agents to overcome the inhibitory effect of raised intracellular Na^+ completely without altering the electrochemical gradient for Na^+ indicates that the inhibition is not caused by a decreased electrochemical driving force for Na^+ - H^+ exchange. Rather, it must be caused by a G protein-mediated feedback

pathway. In this regard, it was further found that inclusion in the pipette solution of antibodies directed against the α -subunit of the G_o protein, which is known to be expressed in salivary endpiece cells (31), abolished the inhibitory effect of 20 mM Na^+ . In contrast, antibodies directed against the α -subunits of G_{i1} , G_{i2} , and G_{i3} were without effect (Fig. 3C).

In the absorptive cell of the salivary duct, $[Na^+]_i$ is sensed by a receptor the effect of which is mediated by G_o (10). This receptor is blocked by amiloride and amiloride analogs such as dimethylamiloride and benzimidazolylguanidinium, thus explaining the ability of these agents to stimulate Na^+ channel activity. It was found that the inclusion of amiloride in the pipette solution reversed the inhibitory effect of 20 mM Na^+ (Fig. 4A). Further, it was found that the inclusion of the activated α -subunit of G_o in the zero Na^+ pipette solution (Fig. 4B) inhibited the Na^+ - H^+ exchanger and that the inclusion of as much as 30 μ M amiloride in the pipette solution was unable to overcome this inhibition (Fig. 4B). Thus, amiloride exerts its inhibitory action upstream of G_o , presumably at the putative receptor for intracellular Na^+ .

Discussion.

It has been previously shown that $[Na^+]_i$ and the G protein, G_o , regulate the activity of the epithelial Na^+ channel in the duct cells of the mouse mandibular gland via Nedd4 (24), a ubiquitin-protein ligase that is believed to bind to Na^+ channels and regulate their activity by ubiquitinating them (12, 13). Here, it was found that feedback inhibition of the Na^+ - H^+ exchanger was not prevented by inclusion in the pipette solution of an antibody directed against Nedd4 or of a fusion protein composed of GST and the three WW-domains of mouse Nedd4 (GST-W), which acts as a dominant negative mutant of Nedd4 (Fig. 4C). This finding is consistent with the low level of expression of Nedd4 in endpiece cells (24). Feedback inhibition was blocked, however, by inclusion of a dominant negative mutant of ubiquitin (K48R) (24) in the pipette solution (Fig. 4C), indicating that feedback regulation of the exchanger nevertheless is mediated by ubiquitination. Because our preliminary data show that NHE1 transfected into COS cells is ubiquitinated (data not shown), the findings indicate that feedback regulation of NHE1 is mediated by ubiquitination of the exchanger protein. The control system then would resemble the control of surface expression of epithelial Na^+ channels by ubiquitination of the channel protein catalysed by Nedd4.

It cannot be excluded however, that the inactivation of NHE1 produced by Na^+ feedback is the result of ubiquitination of a protein associated with the exchanger, as recently has been proposed for the control of the growth hormone receptor by ubiquitination (32). Whatever the mechanism, the present findings taken together with the finding that activity of epithelial Na^+ channels can be rapidly down-regulated by ubiquitination suggest that ubiquitination may be a general mechanism for the rapid control of membrane transport protein activity.

10 **Example 2: Prevention of the progression of diabetic nephropathy and other forms of chronic renal failure by 6-iodoamiloride.**

Materials and methods.

20 mg 6-iodoamiloride tablets may be formulated and taken orally at a dosage of one or two every 6 hours.

15 **Discussion.**

6-iodoamiloride acts by blocking the intracellular Na^+ receptor that controls NHE1 and other sodium-dependent transporters as well as mediating the normal cellular responses to increased intracellular sodium concentration (which include release of cytokines and increased cell growth and proliferation (44)). In this way, cytokine release and cellular proliferation caused by increased intracellular sodium can be treated with 6-iodoamiloride to prevent the cytokine release and cell growth and proliferation that lead to progression of renal failure.

25 **Example 3: Treatment of cells with reduced Na^+ transport with recombinant adenovirus.**

Materials and methods.

Recombinant adenovirus. Recombinant adenovirus including an expressible gene encoding the Na^+ receptor, GILT may be prepared by routine molecular biology techniques (33). Particularly, the clone encoding GILT (SEQ ID NO:1) may be ligated to a suitable mammalian promoter sequence (e.g. CMV (45)) and inserted into a suitable vector for the transfer, by homologous recombination, of the recombinant GILT gene into an adenovirus as described by He et al. (46).

35 **Administration.** The recombinant adenovirus may be formulated and administered in accordance with known methods in the art. In particular,

the recombinant adenovirus may be formulated for administration as a nasal spray or intrabronchial spray or given intravenously (47, 48) or direct injections of muscle or of organs (49). With administration to the respiratory tract (50), the recombinant adenovirus will preferably be administered at a
5 dose of 10^9 plaque forming units (pfu) at intervals between 2 and 4 weeks.

Discussion.

Upon infection of host diseased cells, the adenovirus will bring about the expression of functional GILT protein to decrease Na^+ transport and restore cytosolic ion composition to substantially that of corresponding
10 healthy cells.

Example 4: Prevention of the progression of chronic hypoxic pulmonary hypertension and other forms of pulmonary hypertension by 6-iodoamiloride and other inhibitors of the sodium receptor.

15 Materials and methods.

20mg 6-iodoamiloride tablets may be formulated and taken orally at a dosage of 1 or 2 every 6 hours.

Discussion.

6-iodoamiloride acts by blocking the intracellular Na^+ receptor that
20 controls NHE1 and other sodium-dependent transporters as well as mediating the normal cellular responses to increased intracellular sodium concentration (which include release of cytokines and increased cell growth and proliferation (44). In this way, cytokine release and cellular proliferation caused by increased intracellular sodium can be treated with 6-iodoamiloride
25 to prevent the cytokine release and cell growth and proliferation that lead to progression of pulmonary hypertension due to chronic hypoxia (51).

It will be appreciated by persons skilled in the art that numerous
30 variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

References:

1. Cui Y, Su YR, Rutkowski M, Reif M, Menon AG, Pun RY (1997) Loss of protein kinase C inhibitor in the beta T594M variant of the amiloride-sensitive Na⁺ channel. Proc Natl Acad Sci USA 94:9962-9966.
2. Lifton RP (1996) Molecular genetics of human blood pressure variation. Science 272:676-680.
3. Sweeney FP, Siczkowski M, Davies JE, Quinn PA, McDonald J, Krowlewski AS, Ng LL (1995) Phosphorylation and activity of Na⁺/H⁺ exchanger isoform 1 of immortalized lymphoblasts in diabetic nephropathy. Diabetes 44:1180-1185.
4. Gaspardone A, Ferri C, Crea F, F Versaci, Tomai F, Santucci A, Chiariello L, Gioffre PA (1998) Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X. J. Am coll Cardiol. 32:2031-2034.
5. Neves PL, Faisca M, Gomes V, Cacodcar S, Bernardo I, Anunciada AI, Viegas E, Martins H, da Silva AM (1996) Risk factors for left ventricular hypertrophy: role of Na⁺-Li⁺ countertransport. Kidney Int. 55:S160-S162.
6. Quinn D.A., Du H.K., Thompson B.T., Hales C.A. (1998) Amiloride analogs inhibit chronic hypoxic pulmonary hypertension. Amer. J. Resp. Critical Care Med. 157:1263-1268.
7. Stutts MJ, Canessa CM, Olsen JC, Hanrick M, Cohn JA, Rossier BC, Boucher RC (1995) CFTR as a cAMP-dependent regulator of sodium channels. Science 269: 847-850.
8. Dinudom A, Harvey KF, Komwatana P, Young JA, Kumar S, Cook DI (1998) Nedd4 mediates control of an epithelial Na⁺ channel in salivary duct cells by cytosolic Na⁺. Proc Natl Acad Sci USA 95:7169-7173.

9. Kellenberger S, Gautschi I, Rossier BC, Schild L (1998) Mutations causing Liddle syndrome reduce sodium-dependent downregulation of the epithelial sodium channel in the *Xenopus* oocyte expression system. J Clin Invest 101:2741-2750.
10. Komwatana P, Dinudom A, Young J. A. and Cook D. I. (1998) J. Membr. Biol 162:225-232.
- 10 11. Komwatana P, Dinudom A, Young J. A. and Cook, D. I (1996) Proc Natl Acad Sci USA 93:8107-8111.
12. Staub O, Dho S, Henry P. C., Correa J, Ishikawa T, McGlade J, and Rotin, D. (1996) EMBO J. 15, 2371-2380.
- 15 13. Staub O, Gautschi I, Ishikawa T, Breitschopf K, Ciechanover, A, Schild L, and Rotin D. (1997) EMBO J. 16:6325-6336.
14. Garty H., and Palmer L.G. (1997) Physiol Rev 77:359-396.
- 20 15. Cussac D., Vidal M., Leprince C., Lin W.Q., Cornille F., Tiraboschi G., Roque B.P. and Garbay C. (1999) A Sos-derived petidimer blocks the Ras signalling pathway by binding both the Grb2 SH3 domains and displays antiproliferative activity. FASEB Journal 13:31-38.
- 25 16. Hollinger E.P., Chittenden T. and Lutz R.J. (1999) Bak BH3 peptide antagonises Bcl-x2 function and induces apoptosis through cytochrome C-independent activation of caspases. J. Biol. Chem. 274:13298-13304.
- 30 17. Lang J., Nishimoto I., Okamoto T., Regazzi R., Kiraly C., Weller U., Wollheim C.B. (1995) Direct control of exocytosis by receptor-mediated activation of the heterotrimeric GTPases G_i and G_o or by expression of their active G α subunits. EMBO Journal 14:3635-3644.

18. Lin P., Le-Niculescu H., Hofmeister R., McCaffery J.M., Jin M.,
Hennemann H., McQuistan T., De Vries L., Farquhar M.G. (1998) The
mammalian calcium-binding protein, nucleobindin (CALNUC), is a
Golgi resident protein. *J. Cell. Biol.* 141:1515-1527.
- 5 19. Berman D.M., Wilkie T.M., Gilman A.G. (1998) GAIP and RSG4 are
GTPase-activating proteins for the G_i subfamily of G protein alpha
subunits. *Cell* 86:445-452.
- 10 20. Jordan J.D., Carey K.D., Stork P.J.S., Iyengar R. (1999) Modulation of
Rap activity by direct interaction of Galphao with Rap1GTPase-
activating protein. *J. Biol. Chem.* 274:21507-21510.
- 15 21. Demaurex N, Romanek, RR., Orlowski J, and Grinstein S. (1997) *J. Gen.*
Physiol 109:117-128.
22. Dinudom A, Young JA., and Cook DI. (1993) *J. Membr. Biol.* 135, 289-
295.
- 20 23. Steward MC., Poronnik P, and Cook DI. (1996) *J. Physiol. (London)*
494:819-830.
24. Dinudom A, Harvey K. F., Komwatana, P, Young J. A., Kumar, S, and
Cook D. I. (1998) *Proc Natl Acad Sci USA* 95:7169-7173.
- 25 25. Dinudom A, Komwatana P, Young JA. and Cook DI. (1995) *J. Physiol.*
(London) 487:549-555.
26. Kumar S, Harvey KF, Kinoshita M, Copland NG, Noda M. and Jenkins
30 NA (1997) *Genomics* 40:435-443.
27. Wu ML and Vaughan Jones RD (1997) *J. Mol Cell Cardiol* 29:1131-1140.
28. Orlowski J and Grinstein S. (1997) *J. Biol Chem* 272:22373-22376.
- 35

29. Eckstein F., Cassel D., Levkovitz H, Lowe M. and Sclinger Z. (1979) J. Biol Chem 254:9829-9834.
30. Katada T. and Ui M. (1982) J. Biol Chem 257:7210-7216.
- 5 31. Watson EL, Olver C., D'Silva N., and Belton C. M. (1994) J. Histochem Cytochem 42:41-47.
32. Govers R, ten Broeke, T, van Kerkhof P, Schwartz AL. and Strous GJ. (1999) EMBO J. 18:28-36.
- 10 33. Sambrook J., Fritsch E.S. and Maniatis T. (1989) Molecular Cloning: a laboratory manual, Second Edition, Cold Spring Harbor Laboratory Press, USA.
- 15 34. Ishibashi H, Dinudom A, Harvey KF, Kumar S, Young JA and Cook DI (1999) Proc. Natl. Acad. Sci. USA 96:9949-9953.
35. Counillon L. and Pouysegur J. (2000) J. Biol. Chem. 275:1-4.
- 20 36. Orlowski J. and Grinstein S. (1997) J. Biol. Chem. 272:22373-22376.
37. Romero M.F. and Boron W. (1999) Annu. Rev. Physiol. 61:699-723.
- 25 38. Haas M. and Forbush B 3rd (1998) J. Bioenerg. Biomembr. 30:161-172.
39. Komwatana P., Dinudom A., Young J.A. and Cook D.I. (1996) Proc. Natl. Acad. Sci. USA 93:8107-8111.
- 30 40. Friessmuth M., Beindl W., Nickel P., Ijzerman A.P., Hohenegger M. and Nanoff C. (1996) Mol. Pharmacol. 49:602-611.
41. Gautschi I., Ishikawa T., Breitschopf K., Ciechanover A., Schild L. and Rotin D. (1997) EMBO J 16:6325-6336.
- 35

42. Volchuk A., Narine S., Foster L.J., Grabs D., De Camilli P. and Klip A.
(1998) *Biol. Chem.* 273:8169-8176.
43. Dinudom A., Komwatana P., Young J.A. and Cook D.I. (1995) *J.*
5 *Physiol. (london)* 487:549-555.
44. Stanton B.A. and Kaissling B. (1989) *Am. J. Physiol.* 257:F1-F10.
45. Cummings MM, O'Mullane LM, Barden JA, Cook DI & Poronnik P.
10 (2000) *Cell Calcium* 27: 247-255.
46. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW & Vogelstein BA. A
simplified system for generating recombinant adenoviruses. *Proc. Natl*
Acad. Sci. USA 95: 2509-2514, 1998.
- 15 47. Nemunatis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen
L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS,
Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC,
Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL
20 et al. Adenovirus-mediated p53 gene transfer in sequence with
cisplatin to tumours of patients with non-small-cell lung cancer. *J.*
Clin. Oncol. 18: 609-622, 2000.
48. Dobrzynski E, Yoshida H, Chao J & Chao L. Adenovirus-mediated
25 kallikrein gene delivery attenuates hypertension and protects against
renal injury in deoxycorticosterone-salt rat. *Immunopharmacology* 44:
57-65, 1999.
49. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR,
30 Isom OW & Crystal RG. Six-month assessment of a phase I trial of
angiogenic gene therapy for the treatment of coronary artery disease
using direct intramyocardial administration of an adenovirus vector
expressing VEGF121 cDNA. *Ann. Surg.* 230: 466-470, 1999.
- 35 50. Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker
AL, Kaner RJ, Ferris B, Gonda I, Sweeney TD, Ramalingam R, Kovesdi

- I, Shak S & Crystal RG. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. *J. Clin. Invest.* 104: 1245-1255, 1999.
- 5 51. Quinn DA, Du H-K, Thompson BT & Hales CA. Amiloride analogues inhibit chronic hypoxic pulmonary hypertension. *Am. J. Resp. Crit. Care Med.* 157: 1263-1268, 1998.

Claims:

1. A method of treatment of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na^+ transport protein, the method comprising administering to a subject having said disease an effective amount of an agent that substantially restores the ion composition of the cytosol in said diseased cells to that which is found in corresponding cells from healthy tissue.
2. A method according to claim 1, wherein the Na^+ transport protein is other than an epithelial Na^+ receptor.
3. A method according to claim 1, wherein the Na^+ transport protein is selected from the group consisting of Na^+ - H^+ exchanger 1 (NHE1), Na^+ - H^+ exchanger 2 (NHE2), Na^+ - H^+ exchanger 3 (NHE3), the Na^+ - HCO_3^- cotransporter and the $\text{Na}^+\text{K}^+2\text{Cl}$ cotransporter.
4. A method according to any one of claims 1-3, wherein the abnormal cytosolic ion composition in diseased cells arises from reduced Na^+ transport protein activity.
5. A method according to claim 4, wherein said agent is selected from gene therapy agents and blocking agents of the Na^+ transport protein inhibitory feedback mechanism.
6. A method according to claim 5, wherein said agent is a recombinant adenovirus including a nucleotide sequence encoding a non-mutated Na^+ transport protein which is other than a non-mutated epithelial Na^+ receptor.
7. A method according to claim 5, wherein the agent is selected from amiloride and amiloride analogs.
8. A method according to claim 5, wherein said agent is a G-protein inhibitor.

9. A method according to claim 8, wherein the G-protein inhibitor is selected from GDP- β -S and NF023.
10. A method according to claim 5, wherein said agent is a ubiquitin protein ligase inhibitor.
11. A method according to claim 10, wherein the ubiquitin protein ligase inhibitor is selected from dominant negative mutants of ubiquitin and agents that prevent binding of ubiquitin protein ligase to Na⁺ transport proteins.
12. A method according to any one of claims 1-3, wherein the abnormal cytosolic ion composition in diseased cells arises from over activity of a Na⁺ transport protein.
13. A method according to claim 12, wherein said agent is selected from gene therapy agents, intracellular Na⁺ receptor activators; G-protein activators, ubiquitin ligase activators and endocytosis triggering agents.
14. A method according to claim 13, wherein said gene therapy agent is an adenovirus including a nucleotide sequence encoding a non-mutated protein which participates in the Na⁺ transport protein inhibitory feedback mechanism.
15. A method according to claim 13, wherein said intracellular Na⁺ receptor activator is selected from guanidium and guanidium analogs.
16. A method according to claim 13, wherein said G-protein activator is selected from GDP- γ -S and receptor mimetic peptides.
17. A method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na⁺ transport protein, the method comprising isolating from a subject suspected of having said disease a sample of cells and assessing said sample of cells for reduced or over activity of said Na⁺ transport protein or the Na⁺ transport protein in inhibitory feedback mechanisms.

18. A method according to claim 17, wherein said Na^+ transport protein is other than an epithelial Na^+ receptor.
- 5 19. A method according to claim 17, wherein said Na^+ transport protein is selected from the group consisting of Na^+ - H^+ exchanger 1 (NHE1), Na^+ - H^+ exchanger 2 (NHE2), Na^+ - H^+ exchanger 3 (NHE3), the Na^+ - HCO_3^- cotransporter and the $\text{Na}^+\text{K}^+2\text{Cl}$ cotransporter.
- 10 20. A method according to any one of claims 17 to 19, wherein the sample of cells is a sample of epithelial cells or lymphocytes.
21. A method according to any one of the claims 17 to 20, wherein the sample of cells is assessed for reduced or over activity of Na^+ transport protein by determining the rate of Na^+ -dependent intracellular pH (pH_i) recovery and comparing said rate against similarly measured rates from cells from healthy tissue isolated from said subject or a control subject(s).
- 15 22. A method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased, the method comprising isolating from a subject suspected of having said disease a sample of cells and assessing said sample of cells for over or under expression of the Na^+ transport protein or another protein participating in the Na^+ transport protein inhibitory feedback mechanism.
- 20 23. A method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a Na^+ transport protein, the method comprising isolating a genomic DNA sample from a subject suspected of having said disease and assessing said sample for the presence of a gene encoding a mutated product causative of said reduced or over activity of said Na^+ transport protein.
- 25 30 24. A method of assessing a subject for a predisposition to a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of Na^+ transport protein, the method comprising isolating a genomic DNA sample from a
- 35

subject and assessing said sample for the presence of a gene encoding a mutated product causative of said reduced or over activity of said Na⁺ transport protein.

5 25. A method according to any one of claims 22 or 24, wherein the said Na⁺ transport protein is other than an epithelial Na⁺ receptor.

26. A method according to any one of claims 22 to 24, wherein said Na⁺ transport protein is selected from the group consisting of Na⁺-H⁺ exchanger 1
10 (NHE1), Na⁺-H⁺ exchanger 2 (NHE2), Na⁺-H⁺ exchanger 3 (NHE3), the Na⁺-HCO₃⁻ cotransporter and the Na⁺K⁺2Cl cotransporter.

27. A method according to any one of claims 1 to 26, wherein the said human disease is selected from hypertension, renal failure, cardiac
15 hypertrophy and cardiological syndrome X.

28. An isolated DNA molecule encoding an intracellular Na⁺ receptor designated GILT, said DNA molecule comprising a nucleotide sequence showing ≥ 75% homology to the nucleotide sequence shown as SEQ ID NO:
20 1.

29. A DNA molecule according to claim 28, wherein said DNA molecule comprises a nucleotide sequence showing ≥ 85% homology to the nucleotide sequence shown as SEQ ID NO: 1.

25

30. A DNA molecule according to claim 28, wherein said DNA molecule comprises a nucleotide sequence showing ≥ 95% homology to the nucleotide sequence shown as SEQ ID NO: 1.

30 31. A DNA molecule according to claim 28, wherein said DNA molecule comprises a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 1.

32. A DNA molecule according to claim 28, wherein said DNA molecule
35 encodes a protein comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 2.

33. An isolated DNA molecule encoding an intracellular Na⁺ receptor designated SCunique, said DNA molecule comprising a nucleotide sequence showing $\geq 75\%$ homology to the nucleotide sequence shown as SEQ ID NO: 3.
34. A DNA molecule according to claim 33, wherein said DNA molecule comprises a nucleotide sequence showing $\geq 85\%$ homology to the nucleotide sequence shown as SEQ ID NO: 3.
35. A DNA molecule according to claim 33, wherein said DNA molecule comprises a nucleotide sequence showing $\geq 95\%$ homology to the nucleotide sequence shown as SEQ ID NO: 3.
36. A DNA molecule according to claim 33, wherein said DNA molecule comprises a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 3.
37. A DNA molecule according to claim 33, wherein said DNA molecule encodes a protein comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 4.
38. A host cell transformed with a DNA molecule according to any one of claims 28 to 37.
39. A method of producing an intracellular Na⁺ receptor, comprising culturing the host cell of claim 38 under conditions enabling the expression of said DNA molecule and optionally recovering the expressed receptors.
40. An intracellular Na⁺ receptor designated GILT, said receptor comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 2, in a substantially pure form.
41. An intracellular Na⁺ receptor designated SCunique, said receptor comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 4, in a substantially pure form.

42. An antibody which specifically binds to a receptor according to claim 40 or 41.

5 43. A method for detecting agonist or antagonist agents of the receptor of claim 40 or 41, wherein said method comprises contacting said receptor, or a host cell transformed with and expressing the DNA molecule of any one of claims 28 to 37, with a test agent under conditions enabling the activation of said receptor, and detecting an increase or decrease in activity of the
10 receptor.

44. A nucleic acid probe or primer comprising a nucleotide sequence of 10 or more nucleotides, wherein said probe or primer specifically hybridises to a unique sequence within the DNA molecule of claim 31 or 36 under high
15 stringency conditions.


45. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 5.

20 46. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 6.

47. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 7.


1/5

Figure 1




2/5

Figure 2




3/5

Figure 3




4/5

Figure 4



5/5

Figure 5



Sequence Listing:

5 <110> The University of Sydney
 <120> Methods for diagnosis and treatment of human diseases
 including hypertension
 <160> 7
 10 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 3186
 15 <212> DNA
 <213> Mus musculus
 <400> 1
 20 atggaggcct cctgtctaga gctggccctg gaaggggagc ggctgtgcaa ggcgggggac 60
 ttcaaggcag gtgtggcttt cttcgaggct gctgtgcagg tgggcactga ggacctgaag 120
 aactgagtg ccatctacag ccagctgggc aatgcctact tctacctgaa ggagtatgcc 180
 cgggccctgc agttctacaa acatgacttg ctgctggcac ggaccattgg tgaccgcatg 240
 ggggaggcca aggctagtgg gaacctgggc aacacactca gggccctagg ccgattcgat 300
 gaggcaatcg tctgctgcca acgacacttg gacattgccc aggagcaggg ggacaaggtt 360
 25 ggggaggcga gagcactcta caacattgga aatgtgtacc acgcccaagg caaacagctt 420
 tcctggaatg ctgcacagga ccccgggcac ctgccacctg atgtcccgga gacactgcac 480
 agggcctctg agttttatgg gaggaacctg tctttggtga aggaactagg cgaccgggcg 540
 gcccgaggca gggcctatgg caacctgggt aacacccact acctactggg aaacttcacg 600
 gaggccacaa ccttccacaa agagcgctg gcatcgcca aggagtttgg ggacaaggca 660
 30 gctgagcgga gggcctacag caacctgggc aatgctcaca tcttcttggg gcgctttgat 720
 gtggctgctg aacattacaa gaagacgctg cagctgtctc ggagctccg ggaccaggca 780
 gtggaggctc aggccttgcta cagcctgggc aacacctaca cactgctaca ggactacgag 840
 cgtgctgctg agtaccacct gcggcaccta gtcattgccc aggagctggc tgatagggtg 900
 ggagagggcc gagcatgctg gagcctgggg aacgcctatg tgtccatggg gagccctgca 960
 35 caggccttga cctttgcaa gaaacatctg cagatctccc aggagattgg agaccgaaac 1020
 ggagaactga cagcccgcat gaattattgc cacctgcagc tggccctggg ccggtgact 1080
 agcccgagcag cagcggagaa gccagatctg gctggctatg aggcacaagg agcaagaccc 1140
 aaacggacac agaggctgag tgccgagacc tgggacctgc tgcggctccc cctggaccgg 1200
 gagcagaatg gagagaccca ccacacaggg gactggaggg gtccaggcag ggactcgctt 1260
 40 cccctcccca tgaggagcag gaagtaccag gaaggtccag atgccattga gaggagaccc 1320
 cgggagggta gtcactctcc actggacagt gctgatgtaa gggtagaggt gcctcgtagc 1380
 ggtattccca gggccccgtc ttctgacgag gagtgtttct ttgacctgct gagtaagttc 1440
 cagagcagtc gcatggatga ccagcgctgt cccctggagg aaggccaggc tggggctgct 1500
 gaggccacag ctgccccatc cgtggaggat agagcagctc agtcctccgt gacagcttca 1560
 45 ccacagacag aggagttctt tgacctcatt gccagctccc agagccggcg gctggacgac 1620
 cagagggcta gcgtaggcag cctgcctggg ctacgcatca ccctcaacaa tgtggggcac 1680
 ctccgaggcg acggggacgc ccaggagccg ggggatgagt ttttcaacat gcttatcaaa 1740
 taccagtccct ccaggattga tgaccagcgc tgcccacccc ctgatgtgct gccccgtggc 1800
 cctaccatgc ctgatgagga tttcttcagc cttatccaga gggcgagc taagcggatg 1860
 50 gatgagcagc gtgtggacct tgctgggagt ccagagcaag aggccagtgg gctgcctgat 1920
 ccccgacagc agtgtccacc ggggtgccagc taaggcctcg cccctacagc cagccatacc 1980
 ctactctgga ctctgtaggc tcacggttgt ccacagtggc catgatcccc caataagcca 2040
 aatcttccca aggccatgat ggacagccag ctacagccca gccccttccc actgagccag 2100
 atgggtgggtg cacaaggccc ccccatccca ggtgggtggg gcaggctaga gctgctatat 2160
 55 gggggagggc atgcttctgt ccccatggat ctccacagct tcttgacaggc ctgccctgcc 2220
 ctgccctagg ccgggccttc agcatgttgg ccccgagccc cggtgctgtc cagagtcttt 2280
 tccctcaagc cctgccctgc caaatgtgaa actctgccaa ctctcccaag gccccagag 2340
 gggcttcaag gacttcttct ggtgggggct acagtgtctg ggcattcttc gtccccagc 2400
 tggctcctggg atggctatga aggaggtaca ctctgatctg cctcacgacc ccagggcagg 2460

cactatcctg gcctggctgt gccaaccct gctgaggag attggcagct acaaagtcca 2520
 gacaccctga cctggtagtc cccagccttg cacttggcct ttgaggaaag atggagcttg 2580
 cccctggcag aggggagagg caggtctcca agcatagggt cttgtactag gagtgcctgag 2640
 ctctggctgg tagtgacgt tcatgaggga tcctctcaac tagatccttc agtcctctta 2700
 5 gtagagcatct accttctatt actagggaga tgatatcttg gctttctccc caaggagggg 2760
 tccatatctt aattggacac agggcactgt agttggggtg gagactcagc cagaactgcc 2820
 ggggcatcca tgagacagac ctttcgggac cgtggtccta gttcttgctt acaagtcccta 2880
 taggtagccc tactggaggg ctctgtacaa ctgtctaacc cagggcctct taccagagg 2940
 gccagggcaa gggaaactga ggacccaact tctgagaggg agaggcaaca tcaactctgag 3000
 10 agcagaaaca gatactagag cacaggggtct cgggcgggac atgggtggccg ccccgcatatc 3060
 ttgaatgtac atgcgtatctt attgcttaca tgtgtttgcc atgttggttca tgggtccttt 3120
 ctgacccgag aggtacattt gttttgtttt acccaaaaaa aaaagtctgc caagtgaata 3180
 aaaaaa 3186

15 <210> 2
 <211> 650
 <212> PRT
 <213> Mus musculus

20 <400> 2
 Met Glu Ala Ser Cys Leu Glu Leu Ala Leu Glu Gly Glu Arg Leu Cys
 1 5 10 15

25 Lys Ala Gly Asp Phe Lys Ala Gly Val Ala Phe Phe Glu Ala Ala Val
 20 25 30

Gln Val Gly Thr Glu Asp Leu Lys Thr Leu Ser Ala Ile Tyr Ser Gln
 35 40 45

30 Leu Gly Asn Ala Tyr Phe Tyr Leu Lys Glu Tyr Ala Arg Ala Leu Gln
 50 55 60

35 Phe Tyr Lys His Asp Leu Leu Leu Ala Arg Thr Ile Gly Asp Arg Met
 65 70 75 80

Gly Glu Ala Lys Ala Ser Gly Asn Leu Gly Asn Thr Leu Arg Ala Leu
 85 90 95

40 Gly Arg Phe Asp Glu Ala Ile Val Cys Cys Gln Arg His Leu Asp Ile
 100 105 110

Ala Gln Glu Gln Gly Asp Lys Val Gly Glu Ala Arg Ala Leu Tyr Asn
 115 120 125

45 Ile Gly Asn Val Tyr His Ala Lys Gly Lys Gln Leu Ser Trp Asn Ala
 130 135 140

50 Ala Gln Asp Pro Gly His Leu Pro Pro Asp Val Arg Glu Thr Leu His
 145 150 155 160

Arg Ala Ser Glu Phe Tyr Gly Arg Asn Leu Ser Leu Val Lys Glu Leu
 165 170 175

55 Gly Asp Arg Ala Ala Gln Gly Arg Ala Tyr Gly Asn Leu Gly Asn Thr
 180 185 190

His Tyr Leu Leu Gly Asn Phe Thr Glu Ala Thr Thr Phe His Lys Glu
 195 200 205

60

Arg Leu Ala Ile Ala Lys Glu Phe Gly Asp Lys Ala Ala Glu Arg Arg
 210 215 220
 5 Ala Tyr Ser Asn Leu Gly Asn Ala His Ile Phe Leu Gly Arg Phe Asp
 225 230 235 240
 Val Ala Ala Glu His Tyr Lys Lys Thr Leu Gln Leu Ser Arg Gln Leu
 245 250 255
 10 Arg Asp Gln Ala Val Glu Ala Gln Ala Cys Tyr Ser Leu Gly Asn Thr
 260 265 270
 Tyr Thr Leu Leu Gln Asp Tyr Glu Arg Ala Ala Glu Tyr His Leu Arg
 275 280 285
 15 His Leu Val Ile Ala Gln Glu Leu Ala Asp Arg Val Gly Glu Gly Arg
 290 295 300
 20 Ala Cys Trp Ser Leu Gly Asn Ala Tyr Val Ser Met Gly Ser Pro Ala
 305 310 315 320
 Gln Ala Leu Thr Phe Ala Lys Lys His Leu Gln Ile Ser Gln Glu Ile
 325 330 335
 25 Gly Asp Arg Asn Gly Glu Leu Thr Ala Arg Met Asn Ile Ala His Leu
 340 345 350
 Gln Leu Ala Leu Gly Arg Leu Thr Ser Pro Ala Ala Ala Glu Lys Pro
 355 360 365
 30 Asp Leu Ala Gly Tyr Glu Ala Gln Gly Ala Arg Pro Lys Arg Thr Gln
 370 375 380
 35 Arg Leu Ser Ala Glu Thr Trp Asp Leu Leu Arg Leu Pro Leu Asp Arg
 385 390 395 400
 Glu Gln Asn Gly Glu Thr His His Thr Gly Asp Trp Arg Gly Pro Gly
 405 410 415
 40 Arg Asp Ser Leu Pro Leu Pro Met Arg Ser Arg Lys Tyr Gln Glu Gly
 420 425 430
 Pro Asp Ala Ile Glu Arg Arg Pro Arg Glu Gly Ser His Ser Pro Leu
 435 440 445
 45 Asp Ser Ala Asp Val Arg Val Gln Val Pro Arg Thr Gly Ile Pro Arg
 450 455 460
 50 Ala Pro Ser Ser Asp Glu Glu Cys Phe Phe Asp Leu Leu Ser Lys Phe
 465 470 475 480
 Gln Ser Ser Arg Met Asp Asp Gln Arg Cys Pro Leu Glu Glu Gly Gln
 485 490 495
 55 Ala Gly Ala Ala Glu Ala Thr Ala Ala Pro Ser Val Glu Asp Arg Ala
 500 505 510
 Ala Gln Ser Ser Val Thr Ala Ser Pro Gln Thr Glu Glu Phe Phe Asp
 515 520 525
 60

Leu Ile Ala Ser Ser Gln Ser Arg Arg Leu Asp Asp Gln Arg Ala Ser
 530 535 540
 Val Gly Ser Leu Pro Gly Leu Arg Ile Thr Leu Asn Asn Val Gly His
 545 550 555 560
 Leu Arg Gly Asp Gly Asp Ala Gln Glu Pro Gly Asp Glu Phe Phe Asn
 565 570 575
 Met Leu Ile Lys Tyr Gln Ser Ser Arg Ile Asp Asp Gln Arg Cys Pro
 580 585 590
 Pro Pro Asp Val Leu Pro Arg Gly Pro Thr Met Pro Asp Glu Asp Phe
 595 600 605
 Phe Ser Leu Ile Gln Arg Val Gln Ala Lys Arg Met Asp Glu Gln Arg
 610 615 620
 Val Asp Leu Ala Gly Ser Pro Glu Gln Glu Ala Ser Gly Leu Pro Asp
 625 630 635 640
 Pro Gln Gln Gln Cys Pro Pro Gly Ala Ser
 645 650
 <210> 3
 <211> 2566
 <212> DNA
 <213> Mus musculus
 <400> 3
 aaggaggaca ctgcctggct ggtagctag catcgccgct ccaagactag ccgctcagcg 60
 accacagccg ggttgcctcca ccttaagtcg gaggcgcctg tacacaccct tgggttcggc 120
 tgctctccca gcatccctca cgcgtggacg ccgggcttcc ggacctgggc ggagcccg 180
 ggtttgccg attgctctt cccagcccaa gccttccagc acccggtgcc aggggccatg 240
 gagccccggg cagttgcgga tgccttgag accggagagg aagatgcggt gacagaagct 300
 ctgcggtcgt tcaaccggga gcattctcag agcttcacct tcgatgatgc ccagcaggag 360
 gacaggaaga gactcgcaaa gctactggtc tccgtcctgg agcagggctt gtcaccaaag 420
 caccgtgtca cctggctgca gactatccga atcctatccc gagaccgcag ctgcctggac 480
 tcatttgcca gccgccagag cttacatgca ctgactgct atgctgacat taccgtctca 540
 gaggaaccca tcccacagtc cccagacatg gatgtcctcc tcgagtctct caaatgcctg 600
 tgtaatcttg tgctcagcag tccaacagca cagatgctag cagcagaggc tcgcctgggtg 660
 gtgaggctag cggagcgtgt gggactgtac cgcaagagga gctatcccca cgaagtccag 720
 ttctttgact tgaggctcct tttcctgcta acagcccttc gcacggatgt gcgccagcaa 780
 ctgtttcagg agctgcacgg tgtagcctg ctgactgatg cgctggaact aacactgggc 840
 gtggccccc aagaaaaacc tccggtgatg cttccagccc aagagacgga gagggccatg 900
 gagatcctca aagtgtcttt taatatcacc tttgactctg tcaagaggga agttgatgag 960
 gaagatgctg ccctttaccg gtacctgggg actcttctgc ggcactgcgt gatggttgaa 1020
 gctgctgggg accgcacaga ggagttccac ggccacacgg tgaatctcct ggggaacttg 1080
 cccctcaagt gtttgatgt gcttctggcc ctgagctcc acgaaggatc cttagagttc 1140
 atgggagtta acatggatgt gatcagtgcc ctctcgcct tcctagagaa acgtctgcac 1200
 cagaccaca ggctgaagga atgtgtggca cctgtgctga acgtgttgac agaattgtgc 1260
 cgcatgcacc gtctgccag gaagttcctg aaggccagg tcctgcccc tctgagggat 1320
 gtgaggactc ggcctgaggt gggggacctg cttcgaaaca agcttgtccg cctcatgaca 1380
 cacctggata cagatgtgaa gagagtagct tacacaggc tacgggaatg ctgccggcct cctggctgcc 1440
 agtgtgcccc gattcatcaa gtacacaggc cccgacctg ggccagtact cagaggacga ggacacggac 1500
 aggggectca tggctggggg ccgacctgag ggccagtact cagaggacga ggtggaggag 1560
 acagaggagt acagggaagc caaggccagc atcaaccctg tgactggaag ggtggaggag 1620
 aagccgccta atcctatgga aggatgaca gaggagcaga aggaacatga ggccatgaag 1680

5 ctagtgaaca tgtttgacaa gctctccagg cacagagtca tccaacccat ggggatgagt 1740
 cccaggggtc acctcacttc tctgcaagat gcgatgtgtg agacaatgga gggacagctc 1800
 tcctcagacc ctgactcaga tctgactga agatgccagc ggccttgctc cccttcagaa 1860
 ctggtgctgc ttccagacat gtctgggggt gctgcctcaa gaagccacac ccctctccag 1920
 ctggggagcc cttctctctc ctctccacat ttctgtcatc tgcctttgtt ccagtttctt 1980
 gtgttttaga ctgtggtagt cttaccctct gtgaagacgg ggaaccca cc ttctatttcc 2040
 acaagtgaag ttgtttcttg gatgtggctg cagccacgag cagaattgcc ctggcacata 2100
 aatgaacatg cgtgtatgag ggtggtaatg gagcagggtg cacatgggtg aagcatgact 2160
 gggctggatg ccagcccaga gcccgatgtg ggggcatacg ctgtgtttca aacatttttag 2220
 10 aatctgttga aattgtttaa gtatgtcaga aaacacacca agcgtcatgg ttctgtcttc 2280
 tggcccccact gagcacaggg ctagtggcct cttcttaact ttttggctct ggcgctgcca 2340
 cccactgcag tatccgcata cccaagcctc actagtgttg acaactaact cagtcacaac 2400
 cactggctta gtaattctgt gaaggcgaaa gtaagacaaa gtcaaactctg agattctgag 2460
 gcacagaata caggagagtt tgggacaaga ctgtgtatgt gaagtagtca ggtgaaaggc 2520
 15 tattaacag aaactgattt caaaaaaaaaa aaaaaaaaaa aaaaaa 2566

<210> 4
 <211> 530
 20 <212> PRT
 <213> Mus musculus

<400> 4
 25 Met Glu Pro Arg Ala Val Ala Asp Ala Leu Glu Thr Gly Glu Glu Asp
 1 5 10 15
 Ala Val Thr Glu Ala Leu Arg Ser Phe Asn Arg Glu His Ser Gln Ser
 20 25 30
 30 Phe Thr Phe Asp Asp Ala Gln Gln Glu Asp Arg Lys Arg Leu Ala Lys
 35 40 45
 Leu Leu Val Ser Val Leu Glu Gln Gly Leu Ser Pro Lys His Arg Val
 50 55 60
 35 Thr Trp Leu Gln Thr Ile Arg Ile Leu Ser Arg Asp Arg Ser Cys Leu
 65 70 75 80
 40 Asp Ser Phe Ala Ser Arg Gln Ser Leu His Ala Leu Ala Cys Tyr Ala
 85 90 95
 Asp Ile Thr Val Ser Glu Glu Pro Ile Pro Gln Ser Pro Asp Met Asp
 100 105 110
 45 Val Leu Leu Glu Ser Leu Lys Cys Leu Cys Asn Leu Val Leu Ser Ser
 115 120 125
 Pro Thr Ala Gln Met Leu Ala Ala Glu Ala Arg Leu Val Val Arg Leu
 130 135 140
 50 Ala Glu Arg Val Gly Leu Tyr Arg Lys Arg Ser Tyr Pro His Glu Val
 145 150 155 160
 55 Gln Phe Phe Asp Leu Arg Leu Leu Phe Leu Leu Thr Ala Leu Arg Thr
 165 170 175
 Asp Val Arg Gln Gln Leu Phe Gln Glu Leu His Gly Val Arg Leu Leu
 180 185 190
 60 Thr Asp Ala Leu Glu Leu Thr Leu Gly Val Ala Pro Lys Glu Asn Pro

	195	200	205
	Pro Val Met Leu Pro Ala Gln Glu Thr Glu Arg Ala Met Glu Ile Leu		
	210	215	220
5	Lys Val Leu Phe Asn Ile Thr Phe Asp Ser Val Lys Arg Glu Val Asp		
	225	230	235
	Glu Glu Asp Ala Ala Leu Tyr Arg Tyr Leu Gly Thr Leu Leu Arg His		
10		245	250
	Cys Val Met Val Glu Ala Ala Gly Asp Arg Thr Glu Glu Phe His Gly		
		260	265
15	His Thr Val Asn Leu Leu Gly Asn Leu Pro Leu Lys Cys Leu Asp Val		
		275	280
	Leu Leu Ala Leu Glu Leu His Glu Gly Ser Leu Glu Phe Met Gly Val		
20		290	295
	Asn Met Asp Val Ile Ser Ala Leu Leu Ala Phe Leu Glu Lys Arg Leu		
	305	310	315
	His Gln Thr His Arg Leu Lys Glu Cys Val Ala Pro Val Leu Asn Val		
25		325	330
	Leu Thr Glu Cys Ala Arg Met His Arg Pro Ala Arg Lys Phe Leu Lys		
		340	345
30	Ala Gln Val Leu Pro Pro Leu Arg Asp Val Arg Thr Arg Pro Glu Val		
		355	360
	Gly Asp Leu Leu Arg Asn Lys Leu Val Arg Leu Met Thr His Leu Asp		
		370	375
35	Thr Asp Val Lys Arg Val Ala Ala Glu Phe Leu Phe Val Leu Cys Ser		
		385	390
	Glu Ser Val Pro Arg Phe Ile Lys Tyr Thr Gly Tyr Gly Asn Ala Ala		
40		405	410
	Gly Leu Leu Ala Ala Arg Gly Leu Met Ala Gly Gly Arg Pro Glu Gly		
		420	425
45	Gln Tyr Ser Glu Asp Glu Asp Thr Asp Thr Glu Glu Tyr Arg Glu Ala		
		435	440
	Lys Ala Ser Ile Asn Pro Val Thr Gly Arg Val Glu Glu Lys Pro Pro		
		450	455
50	Asn Pro Met Glu Gly Met Thr Glu Glu Gln Lys Glu His Glu Ala Met		
		465	470
	Lys Leu Val Asn Met Phe Asp Lys Leu Ser Arg His Arg Val Ile Gln		
55		485	490
	Pro Met Gly Met Ser Pro Arg Gly His Leu Thr Ser Leu Gln Asp Ala		
		500	505
60	Met Cys Glu Thr Met Glu Gly Gln Leu Ser Ser Asp Pro Asp Ser Asp		

515 520 525

Pro Asp
530

5

<210> 5
<211> 69
10 <212> DNA
<213> Mus musculus

<400> 5
15 atggcgagcc cggccccgcc cgtggccgag gagctcccg gcccggcctc caggcgccctc 60
tactccagg 69

<210> 6
<211> 201
20 <212> DNA
<213> Mus musculus

<400> 6
25 tgtactgtgg ctgcgtctgc agggctctgtc tggggtgacc ttggcatggt gtccctcttc 60
agaccagggg ccaggggtgc agaaaaactg ccaaggacac tgccatagtc tgcaccctga 120
catgttcctg ttccactgag ggtcacagct acgttttcaa gaagatttag agtggcctgg 180
agagaagagc agagacctgg g 201

<210> 7
<211> 787
<212> DNA
30 <213> Mus musculus

<400> 7
35 cagtcctgcg ctgtgggtgt tactcggagc aggtgttcag acccaaattt ggagcagagg 60
ctaggaacca gctcagtaaa tcagtcggat gcctctggcg ctgctaatac caactggatg 120
gggaggacag gcagaccgga aagagactgg tgaaggagac ggccggggcc tgccactgag 180
taggggcaga gccggttagc acggcggttg acatcatcca ctggagcact gtttgatgt 240
40 gtcactgtgg ggcaccgact cagctaagtg gcgtgcggac ctggctcccc gctacacagc 300
gctcatacgc ttctaacctc agacacgcct cggctggcgg cccctccgtt gctcctctcg 360
cgggagtggc ttttccacgg gtgttcttca cttccttctc tgcaattttc ttgagaataa 420
ccgtattact ttggtggcta ttcttttttag ataggtctgc tagtttctgc ctctcgagt 480
ctgggattta agaaggcgtg cgtcactatg cccggctaac cacgtgcatt attttgacca 540
45 tccaagtggg tgtacttctc ttccctatt ccctatggaa gatgagctcc aaggcctgga 600
tcgcgagaat cgtcttcccc aactgattaa gcggccagga gccggcgctc ccttctttat 660
cacagtacgg ggacaagagc gtaaagagga cggccacgc gcggggccaag ccacacccca 720
ctccccacc tcccatccca ccccccccc cgcctgccag gaactcgggc tagagaggag 780
50 ggctcga 787

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : C12N 15/12; A61K 38/16, 48/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) SEE ELECTRONIC DATABASE BOX BELOW		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE ELECTRONIC DATABASE BOX BELOW		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See extra sheet		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	Takesono, A. et al (1999) "Receptor-independent activators of heterotrimeric G-protein signaling pathways" J. Biol. Chem. 274(47), pages 33202-5. See the entire document.	28-32, 40, 45, 46
PX	Ishibashi, H. et al (1999) Na ⁺ -H ⁺ exchange in salivary secretory cells is controlled by an intracellular Na ⁺ receptor" Proc. Natl. Acad. Sci. USA 96, pages 9949-53 See the entire document	3, 5-11, 14-16, 19, 26
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
"A" document defining the general state of the art which is not considered to be of particular relevance		
"E" earlier application or patent but published on or after the international filing date		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 19 October 2000	Date of mailing of the international search report 23 OCT 2000	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929	Authorized officer TERRY MOORE Telephone No : (02) 6283 2632	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU00/00980

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Harvey, K.F. et al (1999) "All three WW domains of murine Nedd4 are involved in the regulation of epithelial sodium channels by intracellular Na ⁺ " J. Biol. Chem. 274(18), pages 12525-30 See in particular the discussion.	5, 10, 11, 14
X	Komwatana, P. et al (1998) "Activators of epithelial Na ⁺ channels inhibit cytosolic feedback control. Evidence for the existence of a G protein-coupled receptor for cytosolic Na ⁺ " J. Membrane Biol. 162, pages 225-32 See in particular the discussion and figure 7.	5, 7, 8, 15, 16
X	Dinudom, A. et al (1998) "Nedd4 mediates control of an epithelial Na ⁺ channel in salivary duct cells by cytosolic Na ⁺ " Proc. Natl. Acad. Sci. USA 95, pages 7169-73 See in particular the discussion and figure 4.	5, 6, 10, 11, 14
X	Cook, D.I. et al (1998) "Control of Na ⁺ transport in salivary duct epithelial cells by cytosolic Cl ⁻ and Na ⁺ " Eur. J. Morphology 36, Supplement ++pages 67-73 See in particular the summary and figure 8.	5, 7-9, 14, 16
X	Symons, J.D. et al (1998) "Na-H exchange inhibition with cariporide limits functional impairment caused by repetitive ischemia" J. Cardiovascular Pharmacology 32, pages 853-62 See the entire document.	3, 5, 7
X	EP A 726 254 (MITSUI TOATSU CHEMICALS, INC.) 14 August 1996 See page 2, line 120 - page 3, line 3 and claim 10.	3, 5, 7
X	Komwatana, P. et al (1996) "Cytosolic Na ⁺ controls an epithelial Na ⁺ channel via the G _i guanine nucleotide-binding regulatory protein" Proc. Natl. Acad. Sci. USA 93, pages 8107-11 See in particular the discussion and figure 5.	5, 7, 8, 9, 14, 16
X	EP A 622 356 (SUMITOMO PHARMACEUTICALS CO., LTD.) 2 November 1994 See in particular page 3.	3, 5, 7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
3, 5-11, 14-16, 19, 26 and 28-47
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

The international application contains 8 separate inventions. These are:

- Invention 1. Regulating the activity of NHE1 for normalising cytosolic ion concentration.
- Invention 2. Regulating the activity of NHE2 for normalising cytosolic ion concentration.
- Invention 3. Regulating the activity of NHE3 for normalising cytosolic ion concentration.
- Invention 4. Regulating the activity of Na^+HCO^- cotransporter for normalising cytosolic ion concentration.
- Invention 5. Regulation the activity of $\text{Na}^+\text{K}^+\text{2Cl}^-$ cotransporter for normalising cytosolic ion concentration.
- Invention 6. Regulating the activity of any Na^+ receptor for normalising cytosolic ion concentration.
- Invention 7. Sequences 1, 2, 5 and 6 defining GILT sequences and variants.
- Invention 8. Sequences 3, 4 and 7 defining SCunique sequences and non-coding regions thereof.

The feature linking inventions 1-6 resides in the regulation of Na^+ receptors for therapeutic use. However using epithelial Na^+ receptors for therapeutic use is already known. Thus a unity of invention does not exist *a posteriori*.

Inventions 7 and 8 are directed to the identification of new and alternative Na^+ receptors. The only common feature between these two inventions and inventions 1-6 is the Na^+ receptors. Na^+ receptors are already known (see above) and thus no unity exists *a posteriori*. There does not appear to be any common structural feature linking the two sequences defined in inventions 7 and 8 and thus there is no unity of invention *a priori* between these two groups of sequences.

The ISA searched inventions 7 and 8 under one search fee as it does not seem that significant extra effort is involved in combining these two inventions.

An additional search fee was paid and inventions 1-5 were searched under this search fee because it appeared that a single search could be drafted that would encompass all 5 inventions.

As a result the two searches covered the material defined in claims 3, 5-11, 14-16, 19, 26 and 28-47.

Continuation of Box No: B

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Medline, CA, GenPept, SwissProt, EMBL, Genbank: Sequences 1-7, keywords: GILT, SCunique, NHE1, NHE2, NHE3, Na^+/H^+ exchanger, Na^+HCO^- cotransporter, NaKCl cotransporter, sodium channel, cytosolic, intracellular, inhibition, feedback, regulation

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00980

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
EP	622 356	JP	7010839	CN	1106800	CA	2121391
EP	726 254	US	5 627 193	JP	8277269		
							END OF ANNEX